Dry Eyes?

Constant fatigue?

Persistent joint pain?

If this sounds familiar, you might qualify for a Sjögren’s clinical study.

I'm Interested
Elderly woman reading a book, with a coffee mug in hand

For women with Sjögren’s, consider participating in this study looking to evaluate changes in your quality of life.

Can I Participate?

You may be eligible to participate in this study if you:

Are a female between the ages of 18 and 75
Have been diagnosed (by a rheumatologist) with Sjögren’s
Experience moderate-to-severe symptoms of Sjögren’s including fatigue, joint pain, and dryness in the eyes and mouth

No insurance is needed to join this research study!

Other eligibility criteria apply and will be evaluated by a study doctor if you choose to continue screening for the study.

I'm Interested

What is the Purpose of the Resolve Sjögren’s Study?

The purpose of this study is to evaluate whether RSLV-132 can decrease key symptoms of Sjögren’s—such as fatigue, dryness in the eyes and mouth, and joint pain—and to assess its safety and tolerability in people living with Sjögren's.
Group of mature adults attending art class at community centre with teacher
I'm Interested

Why Should I Join the Resolve Sjögren’s Study?

This study is unique because it focuses on how patients feel and aims to improve quality of life. Unlike most drugs in development, which target severe systemic disease and organ involvement, this study specifically addresses the everyday symptoms of Sjögren’s, such as fatigue, dryness, and joint pain. By enrolling in this phase 2 study, you may receive:

Study-related care, testing, and the study drug provided at no cost.
Access to expert physicians with experience managing Sjögren’s and regular monitoring of your Sjögren’s.
A stipend payment for each visit.
Reimbursements and support for travel and accommodations related to study visits may be available.
Insurance is not required to join this study.
I'm Interested

What Should I Expect?

Step 1

Step 1

Submit Online Questionnaire

This questionnaire will ask for your contact information and a few questions about your medical history to determine your eligibility. Then, select a time for a short phone call with PatientWing. Submitting the questionnaire is voluntary and does not require a commitment to participate in the study.
Step 2

Step 2

Speak With PatientWing

PatientWing is partnering with Resolve Therapeutics to help identify potential individuals who may be interested in the Resolve Sjögren’s study. You will have a short call to answer additional questions about your medical history, and PatientWing will help collect your medical records.
Step 3

Step 3

Speak With a Research Site

After your conversation with PatientWing, you will meet the research team who will review your medical records. If the research team thinks you are a good fit, they will schedule a screening visit. The research team will provide more information during your conversations with them. No question is a bad question, so please share your concerns with the team!
Step 4

Step 4

Study Participation

After you've completed the screening period, the research team will notify you about your eligibility. If you are enrolled in the study, you should expect the following:
  • You will visit the site approximately 13 times (once per week for the first two weeks, then every 2 weeks).
  • You will receive the study drug as an intravenous (IV) infusion.
  • You will need to fill out a questionnaire each day that asks about your Sjögren’s symptoms that day. It will take approximately 5 minutes to fill out the daily questionnaire. The questionnaire will be downloaded onto your phone, tablet, or laptop, and you will access and fill out the form electronically at home each day. If you do not have a device to access the internet and fill out the questionnaire, one will be provided to you. If you do not fill out the questionnaire each day, you will be withdrawn from the study. Your information will be transmitted electronically to a secure database using encryption technology and security measures.
I'm Interested

Frequently Asked Questions

Where is the study conducted?
The study is being conducted in the United States. PatientWing will help you identify the best study site for you to visit.
How do I get started?
Complete the questionnaire and enter your information to express interest in the study. You can also email studies@patientwing.com or call +1 (213) 459-2979.
Will I receive compensation if I participate in this study?
Yes, you will receive a stipend for each study visit. The study coordinator can provide you with specific information about compensation.
Has the study drug been tested before?
Yes, the drug has been tested before. It has been proven safe in five previous clinical trials. In a prior Phase 2 study, the study drug significantly improved fatigue associated with Sjögren’s.
Is there a chance I will receive a placebo?
Yes, this study has a 50% chance of receiving a placebo.
Can I leave the study at any time?
You’re free to withdraw from the study at any time as study participation is completely voluntary. Withdrawal will not be used against you nor affect your standard medical care in any way. Please contact the study doctor so that they can safely withdraw your participation in the study.

Stay Connected

Receive marketing communications from PatientWing such as patient stories and relevant clinical trial opportunities.
By clicking subscribe, you consent to PatientWing contacting you in accordance with their Privacy Policy. You will be able to unsubscribe from PatientWing communications at any time.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Have Questions?

At PatientWing, we’re here to support you at every step of the study. You can email, text, call or fill out the form with any questions. We’re here to help.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

About the Study Team

Resolve Therapeutics company logo

About The Sponsor

Resolve is a biopharmaceutical company at the forefront of the emerging field of cell-free nucleic acids in disease. They are developing RSLV-132 and RSLV-145 in a broad range of acute and chronic diseases that are driven by cell-free RNA, cell-free DNA, and Neutrophil Extracellular Traps (NETs).

PatientWing company logo

About PatientWing

Our mission to bring better treatments to more people faster starts with you. We help sponsors find patients to participate in their clinical studies. With our focus on rare and serious conditions and expertise in navigating the enrollment process, we're here for you every step of the way.

TOP